Abstract
The first part of this chapter reviews current challenges involved in attacking multistep oncogenesis and discusses the consequences for therapeutic and chemopreventive strategies, highlighting in particular the probable need to inhibit multiple oncogenic targets in a combinatorial fashion to obtain therapeutic benefit in the majority of cancers. The second part of the chapter will describe the potential role of inhibitors of the heat shock protein (HSP90) molecular chaperone.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Workman P. Scoring a bull’s-eye against genome targets. Curr Opin Pharmacol 2001;1:342–352.
Workman P. Changing times: developing drugs in genomeland. Curr Opin Investig Drugs 2001;2:1128–1135.
Reddy A, Kaelin WG. Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol 2002;2:366–373.
Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001;291:1304–1351.
International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001;409:860–921.
Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2001;417:949–954.
Workman P and Kaye SB (eds.) A Trends Guide to Cancer Therapeutics. Trends Mol Med 2002;8:S1–S73.
Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: Inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:10,031–10,033.
Ponder BA. Cancer genetics. Nature 2002;411:336–341.
Volgestein B, Kinzler K. The multiple nature of cancer. Trends Genet 1993;9:138–141.
Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer research. Nature 2001;411:342–348.
Weinstein IB. Addiction to oncogenes. Science 2002;297:63–64.
Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2001;8:4 (Suppl):S14–S18.
De Bono J, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2001;4 (Suppl): S19–S26.
Giaconne G, Johnson DH, Manegold C, et al. A Phase III clinical trial of ZD1839 (‘Iressa’) in combination with gemacitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT I). Ann Oncol 2002;13 Suppl 5:40.
Johnson DH, Herbst R, Giacoone G, et al. ZD1839 (Iressa) in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): results from a Phase III trial (INTACT 2). Ann Oncol 2002;13 Suppl 5: 4680.
Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2:3–24.
Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2001;8:S55–S61.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57–70.
Rutherford LI, Lindquist S. Hsp90 as a capacitator for morphological evolution. Nature 1998;396:336–342.
Queitshc C, Sangster TA, Linquist S. Hsp90 as a capacitor variation. Nature 2002;417:618–624.
DeBoer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J Antibiot 1970;23:442–447.
Uehara U, Hori M, Takeuchi T, Umezawa H. Phenotypic change from transformed to normal induced by benzoquinoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus. Mol Cell Biol 1986;6:2198–2206.
Whitesell L, Mimnaugh EG, Decosta B, et al. Inhibition of heat shock protein HSP90–pp60-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994;91:8324–8328.
Prodromou C, Roe SM, O’Brien R, et al. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65–75.
Stebbins CE, Russo AA, Schneider C, et al. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239–250.
Prodromou C, Panaretou B, Chohan S et al. The ATPase cycle of Hsp90 drives a molecular ‘clamp’ via transient dimerization of the N-terminal domains. EMBO J 2000;19:4383–4392.
Brunton VG, Steele G, Lewis AD, Workman P. Geldanamycin-induced toxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT diaphorase. Cancer Chemother Pharmacol 1998;41:417–422.
Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumour agent. Cancer Chemother Pharmacol 1995;36:305–310.
Schnur RC, Corman ML, Gallascun RJ, et al. Inhibition of the oncogene product p 185erbB2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem 1995;38:3806–3812.
Schnur RC, Corman ML, Gallascun RJ, et al. ErbB2 oncogene inhibition by geldanamycin derivatives: synthesis, mechanism of action, and structure-activity relationships. J Med Chem 1995;38:3813–3820.
Schulte TW, Neckers LM. The benzoquinone ansamycin 17allylamino-17-deemthoxygeldanamcyin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998;42:273–279.
Kelland L, Sharp S, Rogers P, et al. DT diaphorase expression and tumour cell sensitivity to 17-allylamino, 17demethoxygeldanamycin, and inhibitor of heat shock protein 90. J Natl Cancer Inst 1999;91:1940–1949.
Strethapakdi M, Liu F, Tavorath R, Rosen N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res 2000;60:3940–3946.
Munster PN, Basso A, Solit D, et al. Modulation of Hsp90 function by ansamycins sensitises breast cancer cells to chemotherapy-induced apoptosis in an RB-and scheduledependent manner. Clin Cancer Res 2001;7:2228–2236.
Clarke P, Hostein I, Banerji U, et al. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamno-17demethoxygeldanamycin, an inhibitor of hsp90 molecular chaperone. Oncogene 2000;19:4125–4133.
Hostein I, Robertson D, Di Stefano F, et al. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001;61:4003–4009.
Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev 1998;12:3788–3796.
Fitzsimmons SA, Workman P, Grever M, et al. Reductase enzyme expression across the National Cancer Institute tumour cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259–269.
Smith V, Hobbs S, Court W, et al. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res 2002;22:1993–2000.
Banerji U, Walton M, Raynaud F, et al. Validation of pharmacodynamic endpoints for the Hsp90 molecular chaperone inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG) in a human tumor xenograft model. Proc Am Assoc Cancer Res 2001;42:4473.
Wilson RH, Takimoto CH, Agnew EB et al. Phase I pharmacologic study of 17-(Allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:325.
Banerji U, O’Donnell A, Scurr M et al. Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxy-geldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc Am Soc Clin Oncol 2001;20:326.
Munster PN, Tong W, Schwartz L, et al. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (Pts) with advanced solid malignancies. Proc Am Soc Clin Oncol 2001;20:327.
Erlichman C, Toft D, Reid J, et al. A Phase I trial of 17-allylamino-geldanamycin in patients with advanced cancer. Proc Am Assoc Cancer Res 2001;42:4474.
Chung YL, Troy H, Banerji U, et al. The pharmacodynamic effects of 17-AAG on HT29 xenografts in mice monitored by magnetic resonance spectroscopy. Proc Am Assoc Cancer Res 2002;43:73, abstr 371.
Lui D, Hutchinson OC, Osman S, et al. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer 2002;87:783–789.
Workman P. Challenges of PK/PD measurements in modern drug development. Eur J Cancer 2002;38:2189–2193.
Workman P. How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 2003;9:891–902.
Smith V, Sausville EA, Camalier RF, et al. 17-DMAG (NSC 707545), a water soluble geldanamycin analog, has superior in vitro and in vivo activity compared to the HSP90 inhibitor 17-AAG. Eur J Cancer 2002;38:S60, abs. 189.
Chiosis G, Timaul MN, Lucas B, et al. A small molecule designed to bind to the adenine nucleotide pocket of HSP90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001;8:289–299.
Chiosis G, Huezo H, Lucas B, Rosen N. Development of a purine-based novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 2002;10:3555–3564.
Rowlands MG, Newbatt YM, Turlais F, et al. High throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Clin Cancer Res 2001;7:3749s, abst 475.
Beroza P, Meng F, Bears DJ, et al. Efficient discovery of novel small molecule cancer drugs using Telik’s target-related affinity profiling (TRAP(tm)) technology. Proc Am Assoc Cancer Res 2002;43:37, abst 191.
Banerji U, Walton M, Judson P, Workman P. Combination of the heat shock protein 90 (HSP90) chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin (17AAG) and conventional cytotoxic agents in an ovarian cancer cell line model. Eur J Cancer 2002;38:S52 abst 161.
Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of Hsp90 inhibitors. Current Drug Targets 2003;3:349–358.
Price PJ, Sk WA, Skeen PC, et al. Geldanamycin inhibition of 3-methylcholantrene-induced rat embryo cell transformation. Proc Soc Exp Biol Med 1977;155:461–463.
Workman P. The opportunities and challenges of personalized genome-based molecular theropies for cancer: targets, technologies and molecular chaperones. Cancer Chemother Pharmacol 2003;52:S45—S60.
Workman V. Overview Translating Hsp 90 biology into Hsp 90 drugs. Curr Canc. Drug Targets 2003;3:297–300.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Workman, P. (2004). Pharmacological Intervention With Multistep Oncogenesis. In: Kelloff, G.J., Hawk, E.T., Sigman, C.C. (eds) Cancer Chemoprevention. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-767-3_22
Download citation
DOI: https://doi.org/10.1007/978-1-59259-767-3_22
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-342-8
Online ISBN: 978-1-59259-767-3
eBook Packages: Springer Book Archive